UPDATE: Goldman Sachs Raises Target to $48 on Teva - Teva Pharmaceutical Indus (NYSE:TEVA)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Goldman Sachs reiterates its Neutral rating on Teva (NASDAQ: TEVA) and raises its price target to $48 (previously $44) as the company has a new CEO that may prove a catalyst for faster growth. Goldman Sachs says, "TEVA shares have responded very well to the announcement of the new CEO as investors applaud the board's taking action and the opportunity for change. We expect it will take time for Dr. Levin to form and execute his strategy (he does not take the helm until May). ...While TEVA's fundamental challenges ahead are not insignificant given the eroding twin anchors of Copaxone and the US generics business (which represent roughly 75% of EPS), we note some actions the company could consider to unlock value."TEVA closed at $46.09 a share on Wednesday.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!